BioCentury | Jul 5, 2010

Quogue capitalizes Calistoga: Cancer play Calistoga adds $40M from VCs on top of $30M in 2009

...the investment." Calistoga also will use the round to advance another delta selective PI3K inhibitor, CAL-263...
BioCentury | Mar 18, 2010
Distillery Therapeutics

Indication: Inflammation

...some pan-PI3K inhibitors. Next steps could include testing the dual inhibitors in preclinical cancer models. CAL-263...
BioCentury | Feb 25, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...tool owned by Calistoga Pharmaceuticals Inc. The company has two second-generation PI3K subunit-d inhibitors-CAL-101 and CAL-263-in...
BioCentury | May 11, 2009

Ebb & Flow

...hematologic malignancies in 2010. Also next year, Calistoga hopes to start Phase II testing of CAL-263...
Items per page:
1 - 4 of 4